2026-05-19
Interim report Q1 2026
”We look forward to continuing to advance the clinical development of arfolitixorin with a strengthened cash position and the new regulatory approvals in place,” says CEO, Petter Segelman Lindqvist.
Statements
Interview with partner
“By becoming a shareholder in Isofol, we anticipate closer collaboration on the development of arfolitixorin”
Yoshihiro Arai
CEO and president, Solasia Pharma K.K.
Interview with scientific advisor and principal coordinating investigator
“We are treating patients with metastatic colorectal cancer within this trial, and we are currently still in the dose-optimization phase”
Sebastian Stintzing, M.D.
Scientific advisor and principal coordinating investigator
Interview with scientific advisor
“Arfolitixorin is administered prior to 5-FU, allowing rapid formation of the stable ternary TS complex”
Frits Peters, Ph.D.
Scientific advisor
Upcoming Events
- June 09, 2026 - June 09, 2026
The 8th Biotech Hanse Forum, Sweden - August 25, 2026 - August 25, 2026
Interim report April-June 2026 - November 12, 2026 - November 12, 2026
Interim report July-September 2026
Latest reports and presentations
Last updated: